Dimensional Fund Advisors LP Makes New $1.40 Million Investment in MBX Biosciences, Inc. $MBX

Dimensional Fund Advisors LP purchased a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 46,753 shares of the company’s stock, valued at approximately $1,396,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swiss National Bank bought a new stake in shares of MBX Biosciences in the first quarter worth $1,325,000. Bank of New York Mellon Corp grew its holdings in shares of MBX Biosciences by 6.6% in the 1st quarter. Bank of New York Mellon Corp now owns 80,222 shares of the company’s stock valued at $2,395,000 after acquiring an additional 4,960 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of MBX Biosciences in the first quarter valued at about $8,787,000. Strs Ohio increased its position in shares of MBX Biosciences by 128.6% in the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after acquiring an additional 900 shares during the last quarter. Finally, Aaron Wealth Advisors LLC raised its holdings in MBX Biosciences by 1,568.8% during the first quarter. Aaron Wealth Advisors LLC now owns 1,168,176 shares of the company’s stock worth $34,870,000 after acquiring an additional 1,098,176 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have weighed in on MBX. Mizuho raised their price target on MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Citigroup reiterated an “outperform” rating on shares of MBX Biosciences in a research note on Tuesday, May 12th. Truist Financial increased their price objective on MBX Biosciences from $70.00 to $88.00 and gave the company a “buy” rating in a report on Monday. Citizens Jmp raised their target price on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 12th. Finally, Wall Street Zen downgraded shares of MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $75.62.

MBX Biosciences Trading Up 2.2%

NASDAQ MBX opened at $68.57 on Friday. MBX Biosciences, Inc. has a 1-year low of $9.63 and a 1-year high of $72.64. The company has a 50 day moving average of $55.85 and a 200-day moving average of $40.94. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -28.45 and a beta of 0.10.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.10). On average, equities research analysts forecast that MBX Biosciences, Inc. will post -3.12 earnings per share for the current year.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.